Re-EValuating the Inhibition of Stress Erosions (REVISE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Commonly employed medications used in critically ill patients requiring life support include proton pump inhibitors (PPIs). These medications are thought to prevent gastrointestinal (GI) bleeding from stress-induced ulceration. Despite their widespread use, they do hold some risks which include infection in the form of pneumonia and diarrheal illnesses such as Clostridioides difficile infection (C. difficile). Emerging high-quality studies suggest PPI usage does not influence susceptibility to COVID-19 infection, however some studies suggest PPI use leads to poor outcomes in this population, including prolonged time on life-support and death. While we can appreciate the negative effects of PPI may be magnified in the sickest of patients, namely hospitalized patients with COVID-19, the beneficial or potentially harmful role they play in this population remains unclear.

We aim to build a clinical profile to further describe critically ill patients with COVID-19 in Ontario using the infrastructure of an ongoing multicenter clinical trial of acid suppression. We will identify characteristics that predict poor outcomes among sick COVID patients, examining the impact of PPIs on this population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial

NCT03374800

Gastrointestinal Hemorrhage (Clinically Important, Upper)

COMPLETED PHASE3

Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU

NCT02290327

Stress Ulcer Prophylaxis

COMPLETED PHASE3

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NCT00037570

Peptic Ulcer Hemorrhage

COMPLETED PHASE2

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NCT00040495

Peptic Ulcer Hemorrhage

COMPLETED PHASE3

High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment

NCT00709046

Endoscopy Peptic Ulcer Bleeding +1 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall aims are to further characterize the high-risk population of COVID-19 patients nested within the multicenter REVISE trial. Specifically, we plan 1) to explore the impact of PPIs on mechanically ventilated critically ill COVID-19 patients, 2) describe the clinical course for patients with COVID-19 and identify characteristics that predict poor prognosis, and 3) compare outcomes to patients without COVID-19. The overall research questions are as follows:

1. Do critically ill patients projected to receive mechanical ventilation for \>48 hours with COVID-19 have different clinical outcomes without PPIs?
2. Are there prognostically relevant demographic, biomarker and clinical data to characterize critically ill patients with COVID-19?
3. Do critically ill patients with COVID-19 have significant higher rates of clinically important GI bleeding, 90-day mortality, and rates of infection when compared to a propensity-matched non-COVID REVISE cohort?

To accomplish this, the investigators propose to gather information in patients' medical charts including biomarkers drawn by the ICU team, venous thromboembolism (VTE) and tracheostomy timing, to link with extensive baseline characteristics and outcomes already collected in the REVISE trial (NCT03374800)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 GastroIntestinal Bleeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with COVID-19

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)

Intervention Type OTHER

Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)

Patients without COVID-19

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)

Intervention Type OTHER

Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)

Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Adults ≥18 years old projected to receive invasive mechanical ventilation for ≥48 hours according to the treating physician

Exclusion Criteria

1. Already received invasive mechanical ventilation \>72 hours during this hospital admission
2. Acid suppression for active gastrointestinal bleeding or high risk of bleeding (e.g., current bleeding, peptic ulcer bleeding within 8 weeks, recent severe esophagitis, Barrett's esophagus, Zollinger-Ellison syndrome); \[dyspepsia or gastroesophageal reflux is not an exclusion criterion\]
3. Acid suppression in the intensive care unit for \>1 daily dose equivalent of a proton pump inhibitor or histamine-2-receptor antagonist
4. Dual antiplatelet therapy
5. Combined antiplatelet and therapeutic anticoagulation
6. Pantoprazole contraindication per local product information
7. Palliative care or anticipated withdrawal of advanced life support
8. Pregnancy
9. Previous enrolment in REVISE, or a related trial, or trial for which co-enrolment is prohibited
10. Patient, proxy or physician declines

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No